Clinical Trials Browser

Neoplasm, Residual × Dasatinib × Other hematologic neoplasm × Clear all

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual